EZH2 and glioblastoma: In primary GBM, elevated H3K9me3 levels and reduced pan-Ac-H3-bound RRP22 expression further implicate epigenetic dysregulation in tumor progression.106 Targeting EZH2, KDMs, and HDACs offers promising avenues for overcoming treatment resistance and improving therapeutic outcomes.